Literature DB >> 34148378

KRAS-targeted therapies in advanced solid cancers: drug the undruggable?

Khalil Saleh1, Manal Kordahi2, Tony Felefly3, Hampig Raphael Kourie4, Nadine Khalife5.   

Abstract

Entities:  

Keywords:  KRASG12C mutations; RAS; adagrasib; colorectal cancer; non-small-cell lung cancer; sotorasib

Mesh：

Substances：

Year:  2021        PMID： 34148378     DOI： 10.2217/pgs-2021-0045

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  2 in total

1.  The KRAS-G12C inhibitor: activity and resistance.

Authors:  Jiao Liu; Rui Kang; Daolin Tang
Journal:  Cancer Gene Ther       Date:  2021-09-01       Impact factor: 5.854

Review 2.  Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.

Authors:  Daolin Tang; Guido Kroemer; Rui Kang
Journal:  Mol Cancer       Date:  2021-10-04       Impact factor: 27.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.